Literature DB >> 11931787

Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removal.

Nadine Hamelin1, Agnès Glacet-Bernard, Christophe Brindeau, Gérard Mimoun, Gabriel Coscas, Gisèle Soubrane.   

Abstract

PURPOSE: To compare the visual outcome of two different surgical approaches for subfoveal neovascularization in degenerative myopia: macular translocation and surgical removal of choroidal neovascularization (CNV).
DESIGN: Interventional case series.
METHODS: Retrospectively, 32 eyes with degenerative myopia (axial length over 26 mm or refraction over -6 diopters) and subfoveal CNV of 32 consecutive patients operated on by either surgical removal of CNV or limited macular translocation were reviewed. Surgical removal of CNV was performed in 18 eyes and limited macular translocation with a twofold suture in 14 eyes. The main outcome measurements were best-corrected visual acuity (BCVA) and findings from fluorescein angiography. Postoperatively, mean +/- SD follow up was 14 +/- 15 months (range, 6-48 months) in the removal group and 11 +/- 4 months (range, 6-24 months, P =.37) in the translocation group.
RESULTS: In both groups, there was no significant difference in preoperative age, sex, refractive error, or BCVA. The average of postoperative BCVA was statistically better after macular translocation (10 ETDRS lines or 20/100) than after surgical removal (6 lines 10/125, P =.019). Visual acuity improved by 3.8 lines after macular translocation and was unchanged after surgical removal (-0.7 line, P =.011). Macular translocation was successful in shifting the CNV to an extrafoveal location in 11 out of 14 eyes. Mean foveal displacement of all 18 translocated eyes was 695 +/- 426 microm (range, 100-1520 microm). Recurrence of CNV occurred in seven eyes (39%) after surgical removal and in two eyes (14%) after translocation. Retinal detachment occurred in two eyes in each group.
CONCLUSION: In this retrospective study, eyes with degenerative myopia and subfoveal neovascularization treated with limited macular translocation had better visual acuity recovery than eyes treated with surgical removal of the choroidal neovascularization. Further studies are required to confirm these results.

Entities:  

Mesh:

Year:  2002        PMID: 11931787     DOI: 10.1016/s0002-9394(02)01335-1

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  14 in total

1.  Photodynamic therapy for recurrent myopic choroidal neovascularisation after limited macular translocation surgery.

Authors:  W-M Chan; D S C Lam; D T L Liu; T-H Wong; K S C Yuen
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

Review 2.  Choroidal neovascularisation in pathological myopia: an update in management.

Authors:  W-M Chan; M Ohji; T Y Y Lai; D T L Liu; Y Tano; D S C Lam
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

3.  Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.

Authors:  Izumi Yamamoto; Adam H Rogers; Elias Reichel; Paul A Yates; Jay S Duker
Journal:  Br J Ophthalmol       Date:  2006-07-26       Impact factor: 4.638

Review 4.  Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.

Authors:  Ying Zhu; Ting Zhang; Gezhi Xu; Lijun Peng
Journal:  Cochrane Database Syst Rev       Date:  2016-12-15

Review 5.  Recent trends in the management of maculopathy secondary to pathological myopia.

Authors:  D Mitry; H Zambarakji
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-13       Impact factor: 3.117

6.  Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes.

Authors:  Valentina Sarao; Daniele Veritti; Sara Macor; Paolo Lanzetta
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-06-18       Impact factor: 3.117

7.  Surgical removal of subfoveal choroidal neovascularization in pathologic myopia: a 12-year follow-up study.

Authors:  R Hera; C Chiquet; J P Romanet
Journal:  Int Ophthalmol       Date:  2013-03-29       Impact factor: 2.031

Review 8.  Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy.

Authors:  Kelvin Yi Chong Teo; Wei Yan Ng; Shu Yen Lee; Chui Ming Gemmy Cheung
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

9.  [Photodynamic therapy for severe myopia].

Authors:  I Krebs; S Binder; U Stolba; A Abri
Journal:  Ophthalmologe       Date:  2004-01       Impact factor: 1.059

10.  Single intravitreal ranibizumab for myopic choroidal neovascularization.

Authors:  Saidin Nor-Masniwati; Ismail Shatriah; Embong Zunaina
Journal:  Clin Ophthalmol       Date:  2011-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.